For example, mesenchymal recurrent IDH-wildtype GBM has not shown a survival benefit with gross total resection (GTR) in comparison with the receptor tyrosine kinase (RTK I and II) subclass, which indeed benefits from GTR (139). Here, IDH1 is linked to glioblastoma.